Efficacy Study in Patients With Acne Vulgaris.

Summary

Safety and efficacy study in patients with acne vulgaris

Timeline

Start

2016-10-03

Primary completion

2017-01-24

Completion

2017-03-21

Outcome

Missed primary endpoint

registry analysis (superiority test); ADPS Topical Product vs Placebo Control; p = 0.5947; LS Mean Difference 1.33; ANOVA NCT02935036 ↗

registry analysis (superiority test); ADPS Topical Product vs Placebo Control; p = 0.2912; LS Mean Difference 2.75; ANOVA NCT02935036 ↗

registry analysis (superiority test); ADPS Topical Product vs Placebo Control; p = 0.6920; Percent difference 2.4; Cochran-Mantel-Haenszel NCT02935036 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADPS	Unknown	—	Topical

Indications